ALTHOUGH UNCOMMON, MENINGOCOCCAL DISEASE MOVES FAST AND IS POTENTIALLY FATAL2
Watch the Meningococcal Disease Video
- IN AS FEW AS 24 HOURS the symptoms related to meningococcal disease can progress to death in some cases.2
- 10%-15% DIE from complications associated with meningococcal disease.3
- Of those who survive, 11%-19% SUFFER permanent consequences—including seizures, limb loss, kidney damage, hearing loss, and skin scarring.3-6
- 5%-10% OF ADULTS CARRY the bacterium Neisseria meningitidis asymptomatically. Although asymptomatic carriage is common, few carriers develop invasive meningococcal disease. For the majority of people, carriage is an immunizing process that results in systemic, serogroup-specific protective antibody response.7
Meningococcal disease is an uncommon but serious bacterial infection caused by N. meningitidis.7
MENINGOCOCCAL DISEASE STRIKES FAST
Symptoms of meningococcal disease progress rapidly and are often mistaken for the flu in early stages, but can lead to death within 24 hours in some patients.2,8 Please note that symptoms can vary in the order and timing of appearance and some may not appear at all. Symptoms may differ by age group.
*Hours expressed as medians, for patients 15-16 years of age.6
†Seizure was noted at a median of 26 hours.6
‡Even with appropriate treatment, the fatality rate is 10%-15% for patients with invasive meningococcal disease.2
Data were obtained from parents of test subjects via questionnaire (n=313) or interview with a study investigator (n=135). Parents were asked at what time of day their child’s symptoms began, as well as the time of appearance of predefined clinical features. Additional data were obtained from medical records for the course of illness before admission to the hospital in 448 children (≤16 years of age) with meningococcal disease (345 nonfatal cases; 103 fatal). Diagnosis was confirmed with microbiologic techniques in 83% of cases (n=373). The remainder of children (n=75) were probable cases.
- Prescribing Information for MENVEO.
- Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46(2):S9-S15.
- Meningococcal vaccines for preteens, teens. Centers for Disease Control and Prevention website. http://www.cdc.gov/features/meningococcal/. Updated April 18, 2016. Accessed October 6, 2017.
- Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:231-245. http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed October 6, 2017.
- Slack R, Hawkins KC, Gilhooley L, Addison GM, Lewis MA, Webb NJA. Long-term outcome of meningococcal sepsis-associated acute renal failure. Pediatr Crit Care Med. 2005;6(4):477-479.
- Vyse A, Anonychuk A, Jäkel A, Wieffer H, Nadel S. The burden and impact of severe and long-term sequelae of meningococcal disease. Expert Rev Anti Infect Ther. 2013;11(6):597-604.
- MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. 5th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf. Accessed October 6, 2017.
- Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
- Centers for Disease Control and Prevention website. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis, 2005-2014. http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed October 6, 2017.
- Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics. 2009;124(6):1633-1641.